Browse All

Current Filters

CLEAR FILTER x

TITLE

Risk of acute stroke in young patients with new-onset lupus nephritis: a case series

Author:Wu, Danwei   Han, May   Lee, Sarah   

Session Name:P9: Autoimmune Neurology: Neurosarcoidosis / Vasculitis / Neuro-rheumatology  

Topic:Autoimmune Neurology  

Program Number:P9.028  

Author Institution:Stanford University , Menlo Park, CA  Stanford Stroke Center, Palo Alto, CA  

Effect of Amyloid PET on Clinical Management of Alzheimer’s Disease Medication Therapy: The Khatib Study

Author:Ariko, Taylor   Modjeski, Marisa   Chang, Lun-Ching   Merrifield, Megan   Ripper, Karen   Dowd, Danae   Galvin, James   Camargo, Christian   

Session Name:P11: Aging and Dementia: Neuroimaging 1  

Topic:Aging and Dementia  

Program Number:P11.009  

Author Institution:University of Miami, Miami Lakes, FL  University of Miami Miller School of Medicine, Miami, FL  Florida Atlantic University, Boca Raton, FL  Kane Center, Miami, FL  

Survival and Clinical Characteristics of Patients with Glioblastoma with Primitive Neuronal Component

Author:McGranahan, Tresa   Cimino, Patrick   Costanza, Katelyn   

Session Name:P13: Neuro-oncology: Prognosis and Survival in Brain Tumors  

Topic:Neuro-oncology  

Program Number:P13.004  

Author Institution:University of Washington, Alvord Brain Tumor Center, Seattle, WA  National Institute of Health, Bethesda, MD  University of Washington School of Medicine, Seattle, WA  

Masitinib Shows Prolonged Survival in Amyotrophic Lateral Sclerosis (ALS) Patients with Mild or Moderate Disease Severity at Baseline

Author:Ludolph, Albert   Hermine, Olivier   

Session Name:S33: ALS and Motor Neuron Diseases  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S33.003  

Author Institution:University of Ulm  German Center for Neurodegenerative Diseases, Ulm, Germany  Imagine Institute, INSERM UMR 1163 and CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implication, Paris, France  

Integrated safety summary from Phase 3 clinical trials of IPX203, an extended-release carbidopa-levodopa formulation, in Parkinson disease

Author:Fernandez, Hubert   Hauser, Robert   Hinson, Vanessa   Pavasia, Nirav   Molho, Eric   Zeitlin, Leonid   Visser, Hester   D'Souza, Richard   

Session Name:P1: Movement Disorders: Clinical Trials in Parkinson's Disease 1  

Topic:Movement Disorders  

Program Number:P1.006  

Author Institution:Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH  Movement Disorders Center, Tampa, FL  MUSC, Charleston, SC  Neurology Consultants of Dallas, Dallas, TX  Parkinson's Disease & Movement Dis Ctr, Albany, NY  Quartesian LLC, Princeton, NJ  Amneal Pharmaceuticals, Piscataway, NJ  Amneal Pharmaceuticals, Bridgewater, NJ